Search results
Results from the WOW.Com Content Network
[2] Side effects may include irritation of the vein in which it is given, high blood sugar, and swelling. [2] [3] Excess use may result in low blood sodium and other electrolyte problems. [2] Intravenous sugar solutions are in the crystalloid family of medications. [4] They come in a number of strengths including 5%, 10%, and 50% dextrose. [2]
The cells release the glucose into the bloodstream, increasing blood sugar levels. Hypoglycemia, the state of having low blood sugar, is treated by restoring the blood glucose level to normal by the ingestion or administration of dextrose or carbohydrate foods. It is often self-diagnosed and self-medicated orally by the ingestion of balanced meals.
Type 2 diabetes (T2D), formerly known as adult-onset diabetes, is a form of diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. [6] Common symptoms include increased thirst, frequent urination, fatigue and unexplained weight loss. [3]
For premium support please call: 800-290-4726 more ways to reach us
The main goal of diabetes management is to keep blood glucose (BG) levels as normal as possible. [1] If diabetes is not well controlled, further challenges to health may occur. [1] People with diabetes can measure blood sugar by various methods, such as with a BG meter or a continuous glucose monitor, which monitors over several days. [2]
Eating too much sugar is associated with many of the leading causes of death in the U.S., including heart disease, certain cancers, and type 2 diabetes, among others. But the key phrase here is ...
For type 2 diabetics who are not on insulin, exercise and diet are the best tools. [citation needed] Blood glucose monitoring is, in that case, simply a tool to evaluate the success of diet and exercise. Insulin-dependent type 2 diabetics do not need to monitor their blood sugar as frequently as type 1 diabetics. [46]
Inogen (INGN) delivered earnings and revenue surprises of -10.00% and -5.55%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?